Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 July 2024
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)Product type:GuidanceProgramme:Diagnostics guidancePublished: 9 May 2024
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 February 2024
Early and locally advanced breast cancer: diagnosis and management (NG101)Product type:GuidanceProgramme:NICE guidelineLast updated: 16 January 2024Published: 18 July 2018
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)Product type:GuidanceProgramme:Clinical guidelineLast updated: 14 November 2023Published: 25 June 2013
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 23 June 2015
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 May 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 February 2023
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2022
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA836)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2022
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)Product type:GuidanceProgramme:Medical technologies guidancePublished: 5 October 2022
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 August 2022
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 August 2022
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence (TA810)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 July 2022
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 April 2022
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA725)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 September 2021
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (TA704)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 May 2021
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA687)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 March 2021
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 July 2020
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 June 2020
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 May 2020
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 November 2019
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2019
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 February 2019
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2018
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 March 2018
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 January 2018
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 January 2018
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2017
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2017
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 November 2017Published: 19 July 2017
Advanced breast cancer: diagnosis and treatment (CG81)Product type:GuidanceProgramme:Clinical guidelineLast updated: 16 August 2017Published: 23 February 2009
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 December 2016
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 December 2016
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 December 2016
Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)Product type:GuidanceProgramme:Diagnostics guidancePublished: 7 August 2013
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 October 2012
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 August 2012
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 June 2012
Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 January 2012
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2011
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 February 2011
Image-guided radiofrequency excision biopsy of breast lesions (IPG308)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 July 2009
Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 April 2009
Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 July 2008
Laparoscopic mobilisation of the greater omentum for breast reconstruction (IPG253)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 February 2008
Gemcitabine for the treatment of metastatic breast cancer (TA116)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2007
Endoscopic axillary lymph node retrieval for breast cancer (IPG147)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 14 December 2005
Interstitial laser therapy for breast cancer (IPG89)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 September 2004
Improving outcomes in breast cancer (CSG1)Product type:GuidanceProgramme:Cancer service guidelinePublished: 28 August 2002
Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 March 2002
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)Product type:AdviceProgramme:Medtech innovation briefingPublished: 4 October 2022
Contrast-enhanced spectral mammography for breast cancer (MIB304)Product type:AdviceProgramme:Medtech innovation briefingPublished: 30 August 2022
Artificial intelligence in mammography (MIB242)Product type:AdviceProgramme:Medtech innovation briefingPublished: 5 January 2021
Magseed for locating impalpable breast cancer lesions (MIB236)Product type:AdviceProgramme:Medtech innovation briefingPublished: 17 November 2020
AlignRT in breast cancer radiotherapy (MIB157)Product type:AdviceProgramme:Medtech innovation briefingPublished: 24 August 2018
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)Product type:AdviceProgramme:Medtech innovation briefingPublished: 18 January 2018
L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)Product type:AdviceProgramme:Medtech innovation briefingPublished: 4 July 2017
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)Product type:AdviceProgramme:Medtech innovation briefingPublished: 24 August 2016
ATEC system for vacuum-assisted breast biopsy (MIB43)Product type:AdviceProgramme:Medtech innovation briefingPublished: 10 November 2015
Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions (MIB15)Product type:AdviceProgramme:Medtech innovation briefingPublished: 16 December 2014
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)Product type:AdviceProgramme:Evidence summaryPublished: 13 March 2013
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016
Breast cancer (QS12)Product type:Quality standardLast updated: 16 June 2016Published: 28 September 2011